Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-15 + Dinutuximab + Irinotecan/Temozolomide in Relapsed/Refractory Neuroblastoma
NCT06995872Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant human interleukin-15 in neuroblastoma, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Oct 2025; status: recruiting.
02
Drugs
recombinant human interleukin-15
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06995872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995872.